Alto Neuroscience (ANRO) Common Equity (2023 - 2026)

Alto Neuroscience has reported Common Equity for 4 years, with the latest figure at $3000.0 in Q1 2026.

• Quarterly Common Equity fell 100.0% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3000.0 (down 100.0% YoY) and the FY2025 annual result came in at $151.1 million, changed 0.21% from the prior year.
• Common Equity eased to $3000.0 in Q1 2026 per ANRO's latest filing, from $151.1 million in the prior quarter.
• Over five years, Common Equity peaked at $193.1 million in Q1 2024 and troughed at -$71.7 million in Q4 2023.
• A 4-year average of $67.1 million and a median of $123.4 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 526.99% in 2024, then sank 100.0% in 2025.
• Over 4 years, Common Equity stood at -$71.7 million in 2023, then surged by 311.32% to $151.5 million in 2024, then declined by 0.21% to $151.1 million in 2025, then sank by 100.0% to $3000.0 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3000.0, $151.1 million, and $3000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.